Citations 0
February 3, 1999

Coronary Events With Lipid-Lowering Therapy: The AFCAPS/TexCAPS Trial

Author Affiliations

Margaret A.WinkerMD, Deputy EditorIndividualAuthorPhil B.FontanarosaMD, Interim Co-EditorIndividualAuthor


Copyright 1999 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.1999

JAMA. 1999;281(5):414-419. doi:10-1001/pubs.JAMA-ISSN-0098-7484-281-5-jbk0203

To the Editor: Although AFCAPS/TexCAPS1 resulted in a 37% decrease in heart attacks and other serious manifestations of heart disease, there were 80 deaths among participants treated with lovastatin and 77 deaths among participants treated with placebo. These results are no different than those found in either the Lipid Research Clinics Coronary Primary Prevention Trial (LRC-CPPT)2 or the Helsinki Heart Study (HHS),3 earlier primary prevention studies that also demonstrated a statistically significant decrease in a variety of cardiac end points, but no decrease in total mortality.

First Page Preview View Large
First page PDF preview
First page PDF preview